Moderna Inc (NASDAQ:MRNA) CEO Sells $790,451.76 in Stock

Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 11,046 shares of the stock in a transaction on Friday, July 24th. The shares were sold at an average price of $71.56, for a total value of $790,451.76. Following the sale, the chief executive officer now directly owns 6,693,858 shares in the company, valued at approximately $479,012,478.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, July 22nd, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $79.61, for a total value of $716,490.00.
  • On Monday, July 20th, Stephane Bancel sold 6,326 shares of Moderna stock. The shares were sold at an average price of $83.53, for a total value of $528,410.78.
  • On Thursday, July 16th, Stephane Bancel sold 19,000 shares of Moderna stock. The shares were sold at an average price of $83.92, for a total value of $1,594,480.00.
  • On Thursday, July 9th, Stephane Bancel sold 10,000 shares of Moderna stock. The shares were sold at an average price of $62.04, for a total value of $620,400.00.
  • On Monday, July 6th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $59.53, for a total value of $657,568.38.
  • On Wednesday, July 1st, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $62.92, for a total value of $566,280.00.
  • On Friday, June 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $60.65, for a total transaction of $669,939.90.
  • On Wednesday, June 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $63.25, for a total transaction of $569,250.00.
  • On Monday, June 22nd, Stephane Bancel sold 4,521 shares of Moderna stock. The stock was sold at an average price of $65.92, for a total transaction of $298,024.32.
  • On Friday, June 19th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $64.61, for a total transaction of $713,682.06.

NASDAQ MRNA opened at $79.51 on Thursday. Moderna Inc has a 12 month low of $11.54 and a 12 month high of $95.21. The company has a market capitalization of $29.52 billion, a price-to-earnings ratio of -53.01 and a beta of 0.67. The company’s fifty day moving average price is $68.26 and its two-hundred day moving average price is $44.29.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Moderna had a negative net margin of 963.84% and a negative return on equity of 37.49%. The company had revenue of $8.39 million for the quarter, compared to the consensus estimate of $18.17 million. As a group, research analysts predict that Moderna Inc will post -1.44 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Moderna in the 2nd quarter worth about $68,886,000. Frontier Capital Management Co. LLC lifted its position in shares of Moderna by 15.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 538,960 shares of the company’s stock worth $34,607,000 after buying an additional 72,937 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new position in shares of Moderna in the 2nd quarter worth about $18,642,000. Oregon Public Employees Retirement Fund lifted its position in shares of Moderna by 606.2% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 174,861 shares of the company’s stock worth $11,228,000 after buying an additional 150,101 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of Moderna by 3,109.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 122,969 shares of the company’s stock worth $7,896,000 after buying an additional 119,138 shares during the last quarter. Institutional investors own 52.09% of the company’s stock.

Several equities analysts recently commented on MRNA shares. Chardan Capital reaffirmed a “buy” rating and set a $95.00 price target on shares of Moderna in a research report on Monday. Brookline Capital Management reissued a “buy” rating and issued a $95.00 price objective on shares of Moderna in a research report on Monday, July 13th. Jefferies Financial Group assumed coverage on shares of Moderna in a research report on Monday, July 13th. They issued a “buy” rating and a $90.00 price objective for the company. BMO Capital Markets upped their target price on shares of Moderna from $94.00 to $112.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Needham & Company LLC assumed coverage on shares of Moderna in a research note on Wednesday, July 15th. They issued a “buy” rating and a $94.00 target price for the company. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $88.78.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: VIX – Volatility Index

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.